Occipitofrontal circumference in newborns of betamethasone treated mothers.
Celestona (betamethasone-disodiumphosphate) and Celeston (betamethasone-acetat + betamethasone-disodiumphosphate) given intramuscularly to pregnant women in order to reduce the frequency of respiratory distress syndrome does not reduce the occipitofrontal circumference of the newborn infants. Before the results from the actual work were available an impeding effect of the evolution of the brain was found in the light of animal experiments. The material is comprised of 52 newborn infants whose mothers were treated with Celestona 8 mg daily for 3 days and 46 infants treated with Celeston 12 mg daily for 3 days. The untreated population comprises 1012 newborn infants. Excluded were non-caucasian infants, twins, stillborns and cases of uncertain gestational age. The occipitofrontal circumference in normal infants and those infants treated with betamethasone were compared in Figs. 2 and 3. Focusing only upon cases in which corticoids were given more than 7 days before delivery and in which no placental dysfunction was diagnosed, no differences from the normal were found (Tabs. II and III, and Figs. 3 A and B).
D000818:Animals; D001623:Betamethasone / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000196:embryology; D002508:Cephalometry; D002675:Child, Preschool; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005865:Gestational Age; D006257:Head / Q000033:anatomy & histology*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D011247:Pregnancy; D011295:Prenatal Care / Q000379:methods; D011817:Rabbits; D012737:Sex Factors
D001623:Betamethasone